Canada markets open in 2 hours 8 minutes
  • S&P/TSX

    20,861.10
    +227.83 (+1.10%)
     
  • S&P 500

    4,591.67
    +53.24 (+1.17%)
     
  • DOW

    35,227.03
    +646.95 (+1.87%)
     
  • CAD/USD

    0.7885
    +0.0045 (+0.57%)
     
  • CRUDE OIL

    71.67
    +2.18 (+3.14%)
     
  • BTC-CAD

    64,851.48
    +3,002.83 (+4.86%)
     
  • CMC Crypto 200

    1,323.72
    +63.56 (+5.04%)
     
  • GOLD FUTURES

    1,784.30
    +4.80 (+0.27%)
     
  • RUSSELL 2000

    2,203.48
    +44.17 (+2.05%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,131.50
    +288.75 (+1.82%)
     
  • VOLATILITY

    23.96
    -6.71 (-21.88%)
     
  • FTSE

    7,311.48
    +79.20 (+1.10%)
     
  • NIKKEI 225

    28,455.60
    +528.23 (+1.89%)
     
  • CAD/EUR

    0.7003
    +0.0059 (+0.85%)
     

Medicure Announces Grant of Stock Options

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WINNIPEG, MB, July 30, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's current stock option plan. The grant of Options is subject to the approval of the TSX Venture Exchange.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley"), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving 49 states, Washington D.C. and Puerto Rico. Marley is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.

To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/medicure-announces-grant-of-stock-options-301344839.html

SOURCE Medicure Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/July2021/30/c5371.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting